DIA’s Post

ICER’s value assessment methods can systematically undervalue treatments, which may impact patient access to those treatments and the incentives for future innovation. I spoke with AJMC - The American Journal of Managed Care to share three recommendations to improve ICER's approach: https://lnkd.in/eqgzJUnD

Dive into what's in store for #biopharma and #medtech, and what factors could drive innovation in Deloitte's 2024 Health Care and Life Sciences Outlook article. Read it here: https://bit.ly/48cltwL via Deloitte

Efortless.bio Today! 1. MorphoSys's phase 3 trial of CPI-0610 shows positive results in treating Myelofibrosis MorphoSys today announced topline results of the phase 3 study of CPI-0610(Pelabresib) for the treatment of Myelofibrosis (MF) https://lnkd.in/gVT7_GYu 2. Plus Therapeutics' phase 2 trial of rhenium(186Re) obisbemeda shows longer median overall survival in glioblastoma patients Plus Therapeutics today announced interim results of the phase 2 study of rhenium(186Re) obisbemeda, a radioconjugate, in patients with glioblastoma(rGBM). The study showed a median overall survival(mOS) of 13 months in a group of 15 patients, which was 63% longer than the current standard of care. https://lnkd.in/gS22AGTq 3. Agios Pharmaceuticals's phase 2a trial in LR-MDS demonstrates positive results for anemia treatment Agios Pharmaceuticals today announced interim results of the phase 2a study of AG-946, a potential treatment for anemia in lower-risk myelodysplastic syndromes(LR-MDS). The primary endpoints, including transfusion independence and hemoglobin response, showed promising results in a subset of patients. https://lnkd.in/g7rkU5zX If you would like a free market report on an indication you are interested in, please let me know in any way and I will provide it within 24 hours.

Developing a well-functioning market access strategy in the biotech world can sometimes be tricky. However, with the help of Real-World Evidence (#RWE) you can boost your efforts significantly. Discover how #RWD can provide comprehensive insights into safety, efficacy, and value, empowering healthcare stakeholders to make rapid adjustments to market access strategies and improve patient outcomes in our latest article by Katerina Krinitsyna. Read the full article to learn about real-world data success stories and how Therapyte can be your trusted RWE partner for market access solutions. https://lnkd.in/eaYkkRka #realworldevidence #marketaccessstrategy #healthcareinnovation #therapyte

Deal Cansino biologics partners with SPIMACO to bring menhycia vaccine for meningococcal disease to saudi arabia and key mena markets ➡ https://lnkd.in/gCWSX9PB Saniona and boehringer ingelheim amend ongoing collaboration, for CNS ion channel target drug candidates in schizophrenia treatment, with research funding ➡https://lnkd.in/g7pyNa6f Genequantum healthcare partners with biomap in strategic collaboration for development of novel ADC candidate, utilizing proprietary conjugation technology platforms ➡https://lnkd.in/gadXPbhQ Clinical Trials Sensorion's phase 2a trial of SENS-401 shows preliminary safety data in hearing disorders induced by cisplatin ➡ https://lnkd.in/ggJJJTaa Invivyd's phase 3 trial of INVYMAB shows high serum virus neutralizing antibody titer levels in immunocompromised participants for prevention of symptomatic COVID-19 ➡ https://lnkd.in/grFZ-XFV

📹In this video interview, Chris Dowd, senior vice president of market development, ConnectiveRx, discusses the evolution of drug copay adjustment programs and the circumstances that fueled their controversy across industry, political, and healthcare community circles.

ICYMI - On HealthEconomics.com | A Scientist.com Company, Aetion's Ulka Campbell (Head of Scientific Strategy) discusses FDA's most recent guidance aimed at those populations most underrepresented in #clinicaltrials and how #RWD, #RWE, and #syntheticdata will play a crucial role in addressing issues of representation in health data. Read the full article here: https://hubs.li/Q027BNr90

Bridging the gap between clinical trials and real-world patient experiences is crucial for advancing healthcare. Explore the evolving role of real-world evidence in drug development with insights from Rebecca Miksad, MD, MMS, MPH.

"As companies develop more targeted therapies focused on narrower patient populations, enrolling patients in a traditional control arm is becoming increasingly complex from a cost, time, and ethical standpoint. Constructing regulatory-grade ECAs using data collected from a patient’s electronic health record (EHR), administrative claims, and other sources is of particular interest to cut development time, reduce costs, and ensure participant access to lifesaving therapies." (Deloitte; "Real-world evidence’s evolution into a true end-to-end capability") https://lnkd.in/g8vZExj3

☕You know it’s going to be a day filled with insights when you stumble upon an article about patient-generated data in drug development, all while trying to shake off the morning drowsiness with that first sip of coffee! ☕ Five Key Takeaways: 1. Prioritize early patient involvement in the entirety of the drug development process. 2. Establish a universal standard for terminology in clinical evidence generation. 3. Enhance the predictability of PED requirements. 4. Stress the need for transparency in PED evaluations. 5. Champion the inclusion of PED in Health Technology Assessments (HTAs). Every Stakeholder Has a Role: Regulators: Extend consistent guidance and support, amplifying patient voices. HTA Authorities: Strive for uniformity in PED approaches and synchronize with stakeholders. Industry: Elevate the patient voice, ensuring their distinct needs and preferences take precedence. Academia: Forge the path with cutting-edge research and methodologies. Patient Advocates & Technologies: Turn those invaluable lived experiences into actionable insights. At TrialHub, we're proud to integrate our client's proprietary data with validated patient insights from the public sphere. Our latest tool, TrialHubIQ, is geared to boost patient engagement and foster diversity in #clinicalTrials. (I had to boast a tiny bit). #PatientsFirst #PatientCenteredMedicine #clinicalresearch #patientinsights